Lupeng Pharma Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

LP-108 / Lupeng Pharma

LP-108-I-01, NCT04356846: A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Recruiting

RoW

LP-108 tablet

The First Affiliated Hospital with Nanjing Medical University, Guangzhou Lupeng Pharmaceutical Company LTD., Newave Pharmaceutical Inc

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

12/23

NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Recruiting

198

RoW

LP-108, Azacitidine

Guangzhou Lupeng Pharmaceutical Company LTD.

Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

12/24

12/25

NCT04139434: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Active, not recruiting

Europe, US

LP-108, LP-108 and azacitidine

Newave Pharmaceutical Inc

AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML

01/25

rocbrutinib (LP-168) / Lupeng Pharma

NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting

RoW

Rocbrutinib, NWP-775, LP-168

Guangzhou Lupeng Pharmaceutical Company LTD.

Mantle Cell Lymphoma (MCL)

12/24

12/25

NCT06864507: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

Not yet recruiting

1/2

150

RoW

HS-10561, Placebo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Chronic Spontaneous Urticaria

09/26

12/26

NCT05432713: A Study of LP-168 in Healthy Volunteers

Completed

RoW

LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo

Guangzhou Lupeng Pharmaceutical Company LTD.

Multiple Sclerosis, NMO Spectrum Disorder

11/22

12/22

LP-168-US-I01, NCT04775745: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Recruiting

LP-168

Newave Pharmaceutical Inc

CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia

07/25

12/25

NCT05917964: A Food Effect Study of LP-168 Tablets in Healthy Subjects

Completed

RoW

LP-168 tablet, NWP-775

Guangzhou Lupeng Pharmaceutical Company LTD.

Mantle Cell Lymphoma

08/23

NCT06126861: The Mass Balance Study of LP-168 in Healthy Subjects

Completed

RoW

[14C]LP-168

Guangzhou Lupeng Pharmaceutical Company LTD.

Clinical Pharmacology

02/24

03/24

NCT04993690: A Study of LP-168 in Participants with Relapse or Refractory B-Cell Lymphoma

Recruiting

200

RoW

LP-168 tablet

Guangzhou Lupeng Pharmaceutical Company LTD.

B-cell Lymphoma

12/24

06/25

LP-168-CN301, NCT06251180: Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Recruiting

112

RoW

Rocbrutinib, LP-168, Rituximab, MabThera; Rituximab Biosimilar HLX01; Rituximab biosimilar TQB2303; Henlius; Halpryza, Cyclophosphamide, CTX, doxorubicin, ADM; Adriamycin; DOX; Doxorubin hydrochloride, Vincristin, VCR; Vincrystine, Prednisone, delta.1-Cortisone; 1, 2-Dehydrocortisone

Guangzhou Lupeng Pharmaceutical Company LTD.

B-cell Non-Hodgkin Lymphoma

12/25

12/29

LP-118 / Lupeng Pharma

NCT05025358: A Study of LP-118 in Patients with Advanced Tumors

Active, not recruiting

RoW

LP-118 tablet, NWP-4-76

Guangzhou Lupeng Pharmaceutical Company LTD.

Solid Tumor, Lymphoma, Non-Hodgkin

01/25

12/25

NCT04771572: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting

100

LP-118

Newave Pharmaceutical Inc

Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase

10/25

LP-128 / Lupeng Pharma

NCT05130567: A Study of LP-128 Capsules in Healthy Subjects

Active, not recruiting

104

RoW

LP-128 capsules, NWP-1080, Matching Placebo

Guangzhou Lupeng Pharmaceutical Company LTD.

Chronic Hepatitis b

09/26

12/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

LP-108 / Lupeng Pharma

LP-108-I-01, NCT04356846: A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Recruiting

RoW

LP-108 tablet

The First Affiliated Hospital with Nanjing Medical University, Guangzhou Lupeng Pharmaceutical Company LTD., Newave Pharmaceutical Inc

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

12/23

NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Recruiting

198

RoW

LP-108, Azacitidine

Guangzhou Lupeng Pharmaceutical Company LTD.

Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

12/24

12/25

NCT04139434: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Active, not recruiting

Europe, US

LP-108, LP-108 and azacitidine

Newave Pharmaceutical Inc

AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML

01/25

rocbrutinib (LP-168) / Lupeng Pharma

NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting

RoW

Rocbrutinib, NWP-775, LP-168

Guangzhou Lupeng Pharmaceutical Company LTD.

Mantle Cell Lymphoma (MCL)

12/24

12/25

NCT06864507: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

Not yet recruiting

1/2

150

RoW

HS-10561, Placebo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Chronic Spontaneous Urticaria

09/26

12/26

NCT05432713: A Study of LP-168 in Healthy Volunteers

Completed

RoW

LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo

Guangzhou Lupeng Pharmaceutical Company LTD.

Multiple Sclerosis, NMO Spectrum Disorder

11/22

12/22

LP-168-US-I01, NCT04775745: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Recruiting

LP-168

Newave Pharmaceutical Inc

CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia

07/25

12/25

NCT05917964: A Food Effect Study of LP-168 Tablets in Healthy Subjects

Completed

RoW

LP-168 tablet, NWP-775

Guangzhou Lupeng Pharmaceutical Company LTD.

Mantle Cell Lymphoma

08/23

NCT06126861: The Mass Balance Study of LP-168 in Healthy Subjects

Completed

RoW

[14C]LP-168

Guangzhou Lupeng Pharmaceutical Company LTD.

Clinical Pharmacology

02/24

03/24

NCT04993690: A Study of LP-168 in Participants with Relapse or Refractory B-Cell Lymphoma

Recruiting

200

RoW

LP-168 tablet

Guangzhou Lupeng Pharmaceutical Company LTD.

B-cell Lymphoma

12/24

06/25

LP-168-CN301, NCT06251180: Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Recruiting

112

RoW

Guangzhou Lupeng Pharmaceutical Company LTD.

B-cell Non-Hodgkin Lymphoma

12/25

12/29

LP-118 / Lupeng Pharma

NCT05025358: A Study of LP-118 in Patients with Advanced Tumors

Active, not recruiting

RoW

LP-118 tablet, NWP-4-76

Guangzhou Lupeng Pharmaceutical Company LTD.

Solid Tumor, Lymphoma, Non-Hodgkin

01/25

12/25

NCT04771572: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting

100

LP-118

Newave Pharmaceutical Inc

10/25

LP-128 / Lupeng Pharma

NCT05130567: A Study of LP-128 Capsules in Healthy Subjects

Active, not recruiting

104

RoW

LP-128 capsules, NWP-1080, Matching Placebo

Guangzhou Lupeng Pharmaceutical Company LTD.

Chronic Hepatitis b

09/26

12/26



	Diseases Companies Products Productz Mechanisms of Action Sites